Cost-Effectiveness of Addressing Retinopathy of Prematurity in Rwanda
The cost of screening and anti-VEGF treatment for ROP is substantially less than the indirect cost of vision loss due to ROP. Allocating additional funding towards expansion of ROP screening and treatment is cost-saving from a societal perspective compared to current practice.
Authors
- Scott R. Lambert (ORCID: https://orcid.org/0000-0002-7555-0715)
- Victoria Phillips (ORCID: https://orcid.org/0000-0002-8095-3535)
- Tahvi Frank (ORCID: https://orcid.org/0000-0002-1972-782X)
- Francis Mutangana
- Neil Fleming (ORCID: https://orcid.org/0000-0003-1288-5363)
- Connor J. Alder
- Edmund R. Becker (ORCID: https://orcid.org/0000-0003-0265-3980)
- Sherwin J. Isenberg
Institutions
- Brigham Young University (US)
- Emory University (US)
- Baylor University (US)
- University of California, San Francisco (US)
- UCLA Health (US)
- Stanford University (US)
Publication Details
- Journal
- Ophthalmic Epidemiology
- Published
- 2024-08-15
- DOI
- https://doi.org/10.1080/09286586.2024.2372803
- Citations
- 3
- Primary Topic
- Retinopathy of Prematurity Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.21
Funders
- Brigham Young University